Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)-Proposal for a Guide.

BNCT bioprofiling boron carriers drug development in vitro methods pre-clinical testing

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 05 03 2024
revised: 24 04 2024
accepted: 03 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: epublish

Résumé

Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized methods to be used in the early stages of boron carrier development in vitro. The selection of assays and corresponding methods is based on the practical experience of the authors and is certainly not exhaustive, but open to discussion. The proposed tests/characteristics: Solubility, lipophilicity, stability, cytotoxicity, and cellular uptake apply to both low molecular weight (up to 500 Da) and high molecular weight (5000 Da and more) boron carriers. However, the specific methods have been selected primarily for low molecular weight boron carriers; in the case of high molecular weight compounds, some of the methods may need to be adapted.

Identifiants

pubmed: 38786022
pii: cells13100798
doi: 10.3390/cells13100798
pii:
doi:

Substances chimiques

Boron Compounds 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Science Center
ID : 2015/16/W/ST5/00413
Organisme : Ministry of Science and Higher Education
ID : POL-OPENSCREEN (decision no. DIR/WK/2018/06 of October 24, 2018)

Auteurs

Zbigniew J Leśnikowski (ZJ)

Laboratory of Medicinal Chemistry, Institute of Medical Biology PAS, Lodowa 106, 93-232 Lodz, Poland.

Filip Ekholm (F)

Department of Chemistry, University of Helsinki, P.O. Box 55, FI-00014 Helsinki, Finland.

Narayan S Hosmane (NS)

Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, IL 60115, USA.

Martin Kellert (M)

Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany.

Eiji Matsuura (E)

Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-0005, Japan.

Hiroyuki Nakamura (H)

Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8501, Japan.

Agnieszka B Olejniczak (AB)

Screening Laboratory, Institute of Medical Biology PAS, 106 Lodowa, 93-232 Lodz, Poland.

Luigi Panza (L)

Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany.
Dipartimento di Scienze del Farmaco, Università degli Studi del Piemonte Orientale "A. Avogadro", L.go Donegani, 2/3-28100 Novara, Italy.

Louis M Rendina (LM)

School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.

Wolfgang A G Sauerwein (WAG)

Deutsche Gesellschaft für Bor-Neutroneneinfangtherapie DGBNCT e.V., University Hospital Essen, 45122 Essen, Germany.
Department of Radiation Oncology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH